Clarity Pharmaceuticals Ltd. (AU:CU6) has released an update.
Clarity Pharmaceuticals has announced that its cancer treatment clinical trials remain on track despite a recent industry-wide shortage of actinium-225, as their treatments use copper-67 sourced from the US, ensuring no disruptions. Promising results have emerged from their clinical trials, with a patient showing a complete response to their innovative Cu-67 based product. The company emphasizes its commitment to advancing cancer treatment through sustainable and reliable means, focusing on Targeted Copper Theranostics for both children and adults.
For further insights into AU:CU6 stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
